We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PIPR:NYSEPiper Sandler Companies Analysis

Data as of 2026-07-27 - not real-time

$76.71

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Piper Sandler (PIPR) trades at $76.71, comfortably above its 20‑day SMA (74.48) but still below the 50‑day (77.21) and 200‑day (81.82) averages, signaling a short‑term pullback within a longer‑term uptrend. Revenue growth of 32.8% and ultra‑high gross margins (91%) underpin a robust earnings profile, while ROE of 22% and ROA of 16% demonstrate efficient capital use. Technical indicators are mixed: RSI sits near neutral (51.8), MACD histogram is positive (0.45) and flagged bullish, yet volume is decreasing and the 30‑day volatility is elevated at 36%, reflecting a cautious market tone.
Analyst sentiment remains positive (Buy) with a median price target of $88.75, implying ~15% upside, and the DCF‑derived fair value of $191.7 suggests the stock is markedly undervalued on a discounted cash‑flow basis. The dividend yield of 0.95% is modest but the payout ratio of 17% indicates a sustainable dividend supported by ample cash ($830M) and a net‑cash balance after debt.
Overall, the company’s strong growth trajectory, solid profitability, and attractive valuation relative to peers and intrinsic models outweigh the near‑term bearish technical bias and heightened market volatility.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Bullish MACD histogram indicating near‑term momentum
  • Support level around $70.27 providing downside cushion
  • Current price still below analyst median target, offering ~15% upside

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong revenue growth (33%) and high operating margins
  • Forward P/E of 13.7 suggesting attractive valuation relative to earnings
  • Sustainable dividend with low payout ratio and strong cash position

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Long‑term DCF fair value far above current price, indicating substantial undervaluation
  • Consistent high ROE and ROA reflecting durable competitive advantage
  • Net‑cash balance and low debt‑to‑equity risk supporting future strategic investments

Key Metrics & Analysis

Financial Health

Revenue Growth32.80%
Profit Margin13.97%
P/E Ratio19.4
ROE22.17%
ROA16.48%
Debt/Equity7.33
P/B Ratio3.9
Op. Cash Flow$502.1M
Industry P/E18.0

Technical Analysis

TrendBearish
RSI51.8
Support$70.27
Resistance$78.65
MA 20$74.48
MA 50$77.21
MA 200$81.82
MACDBullish
VolumeDecreasing
Fear & Greed Index87.79

Valuation

Fair Value$191.69
Target Price$88.13
Upside/Downside14.88%
GradeUndervalued
TypeGrowth
Dividend Yield0.95%

Risk Assessment

Beta1.39
Volatility36.13%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.